Trial Profile
A Randomized (Phase II), Double-blind, Multicenter Phase I/II trial of Pemetrexed, Carboplatin plus or minus Sorafenib in the First-line Treatment of Patients with Stage IIIb or IV Non-Small Cell Lung Cancer.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Mar 2014
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PECASO
- 27 Dec 2012 Additional lead trial centre added as reported by German Clinical Trials Register.
- 01 Aug 2012 New source identified and integrated (DRKS00003807: German Clinical Trials Register).
- 13 Jul 2011 New source identified and integrated (European Clinical Trials Database record, EudraCT2006-005970-26).